AFFINITY BIOTECH APPOINTS TWO BOARD MEMBERS TO NEW SEATS AND APPOINTS NEW DIRECTOR OF ANALYTICAL SCIENCES
AFFINITY BIOTECH APPOINTS TWO BOARD MEMBERS TO NEW SEATS
AND APPOINTS NEW DIRECTOR OF ANALYTICAL SCIENCES
BOOTHWYN, Pa., Sept. 29 /PRNewswire/ -- Affinity Biotech, Inc. (NASDAQ: AFBI) today announced that it has added two new members to its board of directors, increasing the board to 14. Affinity also appointed Nathan R. Tzodikov, Ph.D., to the newly-created position of Director of Analytical Sciences.
The new board members are Frederick M. Danziger, Esquire, and Geraldine A. Henwood, Ph.D. Mr. Danziger is a partner with the New York-based law firm of Mudge Rose Guthrie Alexander & Ferdon, where he specializes in corporate and financial transactions. He now serves on the board of directors of Culbro Corporation and Bloomingdale Properties, Inc.
Dr. Henwood, who has been a member of the company's Scientific Advisory Board, is president and CEO of Bio-Pharm Clinical Services, Inc. based in Blue Bell, Pa. Bio-Pharm assists pharmaceutical and biotechnology companies with clinical development activities and the regulatory approval process.
Dr. Tzodikov, who received a Ph.D. in organic chemistry from MIT, has many years of experience in the analytical instruments industry. He comes to Affinity from Bio-Rad/Sadtler. Bio-Rad is a multinational manufacturer and distributor of laboratory reagents and instruments for research and diagnostics. Dr. Tzodikov has previously worked for General Electric NMR Instruments and DuPont/New England Nuclear Products. As Affinity's Director of Analytical Sciences, he will focus on the detailed characterization of Affinity's microemulsion drug delivery formulation and lead the company's efforts in assuring quality control for its products.
"Nathan Tzodikov is an important addition for Affinity. As our analytical requirements grow, his knowledge of instrumentation will be a significant asset to the company," said Alan F. Dickason, Ph.D., CEO of Affinity. "Additionally, Mike Danziger brings great financial expertise to our board and Gerri Henwood's guidance with respect to our clinical and regulatory activities could be invaluable to us as we move our products into clinical trials."
Based in Boothwyn, Pa., Affinity Biotech focuses on the development of oral drug delivery systems for proteins and other therapeutic agents, taste masking of therapeutic agents, the development of synthetic blood and other microemulsion-based pharmaceutical products.
/CONTACT: Wayne B. Weisman, executive vice president of Affinity Biotech, Inc., 215-497-0500, or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, for Affinity Biotech, Inc./
(AFBI) CO: Affinity Biotech, Inc. ST: Pennsylvania IN: MTC SU: PER
LR-OS -- NY010 -- 4244 09/29/92 09:17 EDT